The Effect of Chinese Rhubarb, *Rheum officinale*, with and without Benazepril on the Progression of Naturally Occurring Chronic Kidney Disease in Cats

A.S. Hanzlicek, C.J. Roof, M.W. Sanderson, and G.F. Grauer

**Background:** Renal fibrosis is common in progressive kidney disease. Transforming growth factors β (TGF-β) are important mediators of all types of fibrosis, including renal fibrosis. Chinese rhubarb has been shown to have antifibrotic properties in part because of inhibition of TGF-β and has slowed the progression of kidney disease in rodent models.

**Hypothesis:** That administration of a Chinese rhubarb supplement will slow the progression of chronic kidney disease (CKD) in cats and the concurrent administration of Chinese rhubarb and benazepril will be more effective than either alone.

**Animals:** Twenty-nine client-owned cats with naturally occurring IRIS Stage 2 or early Stage 3 CKD and without concomorbidity such as cancer, urinary tract obstruction, urinary tract infection, poorly controlled hyperthyroidism, or systemic hypertension were enrolled in the study.

**Methods:** A randomized, positive-controlled, prospective study was performed. Cats received Chinese rhubarb, benazepril, or both in addition to standard treatment for CKD. Repeated measures ANOVA was used to assess changes in serum creatinine concentration, body weight, hematocrit, urine protein: urine creatinine ratio (UPC), and systemic arterial blood pressure over time between and within treatment groups over an average of 22 months.

**Results:** No significant differences were detected in serum creatinine concentration, body weight, hematocrit, UPC, and systemic arterial blood pressure over time between or within treatment groups. The progression of CKD was not detected in cats treated with Chinese rhubarb, benazepril, or both. Further study in specific subsets of cats with CKD is warranted.

**Conclusions and Clinical Importance:** This study failed to detect a significant difference in the progression of CKD in cats treated with Chinese rhubarb, benazepril, or both. Further study in specific subsets of cats with CKD is warranted.

**Key words:** Cat; Chronic renal failure; Herb; Herbal; Rheum.

**Abbreviations:**

- ANOVA: analysis of variance
- CBC: complete blood count
- CKD: chronic kidney disease
- IRIS: International Renal Interest Society
- RAAS: renin-angiotensin-aldosterone system
- TCC: transitional cell carcinoma
- TGF-β: transforming growth factors β
- TT4: total thyroxine
- UPC: urine protein: urine creatinine

- *Rheum officinale* has been tested for thousands of years to treat various diseases in traditional Chinese medicine. Chinese rhubarb and its constituents have been shown to have antifibrotic and anti-inflammatory effects in vitro and in vivo at least in part because of inhibition of TGF-β. In addition, in rodent models, rhubarb supplementation has decreased proteinuria and slowed progression of kidney disease. These effects appear to be synergistic with concurrent renin-angiotensin-aldosterone system blockade. The purpose of this study was to investigate the effects of a Chinese rhubarb supplement on the progression of naturally occurring CKD in cats. Our hypothesis was that a Chinese rhubarb supplement would slow the progression of CKD in cats and a Chinese rhubarb supplement and benazepril together would be more effective than either alone.
Materials and Methods

Cats

Cats were recruited from the Kansas State University Veterinary Medical Teaching Hospital patient population and from surrounding primary care veterinary hospitals. The study was approved by the Institutional Animal Care and Use Committee of Kansas State University and written owner consent was obtained before patient entry into the study.

Inclusion Criteria

Cats were required to have IRIS Stage 2 or early Stage 3 CKD, as indicated by a serum creatinine concentration of 1.6–3.5 mg/dL in a euhydrated state with a concurrent USG <1.030. Short-term stable disease was evidenced by demonstrating <20% change in serum creatinine concentration from initial evaluation to the first follow-up evaluation 10–14 days later to rule out acute kidney disease, acute-on-chronic kidney disease, and prerenal azotemia. The patient’s temperament had to be such that the required diagnostic evaluations and drug administration would not cause undue risk to the clinician, veterinary student, technical staff, pet owner, or the cat.

Exclusion Criteria

Cats with evidence of comorbidities or consequences of CKD including bacterial pyelonephritis, neoplasia, nephro- or ureterolithiasis, uncontrolled hyperthyroidism, systemic hypertension requiring treatment (Doppler measured blood pressure >170 mmHg on 2 occasions or >160 mmHg with evidence of target organ damage), or other unrelated disease leading to clinical illness resulted in exclusion. Renal proteinuria was not considered an exclusion criterion.

Study Design

A prospective, randomized, positive-controlled study was conducted. Cats that fulfilled the inclusion criteria were randomly placed into 1 of 3 treatment groups: rhubarb supplement, benazepril, or both. Rhubarb supplement was initially administered as 75 mg PO q24h and increased to 75 mg PO q12h at 1 month (manufacturer recommended dose). Benazepril was administered at approximately 0.5 mg/kg PO q24h, with the dose rounded to the nearest 1.25 mg.

Initial Hospital Visit

Initial investigation to diagnose CKD and rule out comorbidities included CBC, serum biochemistry, urinalysis, UPC, species-specific semiquantitative urine albumin ELISA, aerobic bacterial urine culture, total thyroxine concentration, thoracic radiography, abdominal radiography and ultrasound examination, and Doppler-measured blood pressure. In addition, historical findings, physical examination findings, and body weight were recorded.

Subsequent Hospital Visits

A follow-up examination was scheduled at 10–14 days and if renal excretory function was stable (<20% change in serum creatinine concentration), the cat was included in the study. Additional examinations occurred at 1 month after inclusion in the study and every 3 months thereafter. More frequent visits could be scheduled at the discretion of attending clinician, referring veterinarian, or pet owner. A CBC, serum biochemistry, urinalysis, UPC, species-specific semiquantitative urine albumin ELISA, and Doppler-measured blood pressure were performed at each examination, excluding the CBC which was not performed at the first follow-up visit. In addition, a bacterial urine culture and total thyroxine (TT4) concentration were performed every 6 months and abdominal radiography, ultrasound examination, or both were performed every 12 months. Finally, historical findings, physical examination findings, and body weight were recorded at each visit. Included in the historical findings was information regarding possible adverse effects of the medications and difficulty administering them. Verbal confirmation of medication administration compliance was obtained at each hospital visit.

Blood Sample Collection and Analysis

Pet owners were instructed to withhold food but not water for at least 12 hours before hospital visits. Blood samples were collected from the jugular or medial saphenous vein. Serum biochemistry, CBC, and TT4 were performed on the day of the visit.

Urine Sample Collection and Analysis

All urine samples were collected by cystocentesis. Urinalysis was performed using a refractometer for USG, commercially available reagent strips for chemical evaluation, and standard microscopic sediment examination. Approximately 0.5 mL of urine was saved from each urine sample and refrigerated until submitted, on the same day, for aerobic culture and sensitivity. Aerobic urine cultures were performed every 6 months or sooner, if pyuria, bacteriuria, or both were observed in the urine sediment. Urine protein was quantified using the benzethonium reaction method and urine creatinine was quantified using the buffered Jaffe reaction, both with an automated chemistry analyzer. The UPC was calculated from this data for each urine sample. The UPC for a specific visit was not included in statistical analysis in the case of (1) pyuria (>10 WBC/hpf), (2) a positive bacterial urine culture, (3) gross hematuria, (4) spermaturia, or (5) bacteriuria, except for the presence of cocci without pyuria or a positive urine culture. In addition, each urine sample was analyzed for microalbuminuria using a commercially available species-specific urine albumin ELISA according to package insert instructions. Finally, all urinalyses urine cultures were performed on the day of visit.

Blood Pressure Measurement

Systolic blood pressure measurements were obtained by use of an ultrasonic Doppler monitor after the cat was acclimated to the hospital environment. The cat was placed in lateral recumbency. The up forelimb was used for pressure measurement with a neonatal #2 or #3 cuff (width approximately 35–40% the circumference of the leg) placed directly below the elbow. After clipping directly over the common digital branch of the radial artery, 3–4 readings were obtained and the mean was recorded.

Imaging

Thoracic radiographs, abdominal radiographs, and abdominal ultrasound examination findings were interpreted by a board-certified veterinary radiologist. When required, ketamine
commercially available renal specific diet. All cats were slowly, over at least a 14-day period, transitioned to a renal-specific diet if not already consuming the diet starting at the first hospital visit. For cats that did not accept the initially offered commercially available diet, 1 of 2 alternative commercially available diets was offered.

**Diet**

All cats were exclusively fed a commercially available renal specific diet. All cats were slowly, over at least a 14-day period, transitioned to a renal-specific diet if not already consuming the diet starting at the first hospital visit. For cats that did not accept the initially offered commercially available diet, 1 of 2 alternative commercially available diets was offered.

**Treatment**

Medical treatment of CKD was at the discretion of the attending clinician based on the following guidelines. Although hypertension requiring treatment was an exclusion criterion, if a cat became hypertensive (systolic blood pressure ≥170 mmHg on >1 visit or systolic blood pressure >160 mmHg and evidence of target organ damage) after inclusion into the study, amlopidine was started at 0.625 mg PO q24h. The dosage was increased as needed to maintain a systolic blood pressure <160 mmHg. Severe hypokalemia (clinical signs of myopathy) was treated with IV potassium supplementation in the form of potassium chloride followed by PO supplementation. Mild or moderate hypokalemia (serum potassium concentration below reference interval but without signs of myopathy) was treated with PO supplementation on an outpatient basis. Potassium gluconate was prescribed at 2 mEq PO q12h. This dose was increased as needed to maintain serum potassium concentration within the reference interval. If a cat was previously receiving SC fluids at inclusion in the study, this treatment was continued. Bacterial urinary tract infections were treated with an appropriate antibiotic based on urine culture and sensitivity testing and followed up with a repeated bacterial culture within 1 week of discontinuing antibiotic treatment.

**Cause of Death**

Kidney-related death was defined as death or euthanasia because of the progressive decline of kidney function or the consequences thereof. This classification required documentation of an increased serum creatinine concentration (>20% from last hospital visit) and clinical signs associated with azotemia including but not limited to anorexia, weight loss, gastrointestinal upset, uremic ulcers, and lethargy. Nonkidney-related death was defined as death or euthanasia, in which there was not a substantial increase in serum creatinine concentration (<20% from last hospital visit) and an unrelated disease process was determined to play a substantial role in the patient’s deterioration.

**Statistical Analysis**

Analyses were performed using commercial software. Descriptive statistics were presented as mean ± SD. Age, body weight, hematocrit, blood pressure, serum creatinine concentration, and UPC were compared between groups at enrollment by ANOVA. Mean duration of study enrollment was compared between groups by ANOVA. Change in body weight, hematocrit, blood pressure, serum creatinine concentration, and UPC was compared within groups and between groups over time by repeated measures ANOVA. A treatment by visit interaction term was included in all repeated measures models. All participants were included in the statistical analysis except cats with <3 months of treatment as participants in the study. Significance was set at P ≤ .05.
causes of death in these 3 cats included persistent periuria, bilateral renal transitional cell carcinoma (TCC), and unknown. The cat with periuria had multiple negative aerobic bacterial cultures and crepitus on palpation of multiple joints. This cat failed to improve by providing an additional litter box without a climb-up step and medical treatment for osteoarthritis. The second cat was euthanized because of an acute deterioration in renal function. Bilateral renal TCC was found at necropsy and therefore this euthanasia was not attributed to natural progression of CKD. A third cat died of unknown causes and no postmortem examination was performed. Based on contemporaneous laboratory results and clinical signs, this death was categorized as nonkidney related. The numbers of all cause deaths in Groups I, II, and III were 3, 2, and 4 cats, respectively. Because of the low rate of kidney-related death, survival analysis was not performed.

One cat, from Group II, required hospitalization and treatment related to CKD. This cat required IV fluids and potassium supplementation. This cat later was euthanized because of complications of CKD. Five cats required PO potassium supplementation; the number of cats from Groups I, II, and III were 3, 1, and 1, respectively. Five cats received SC fluids at home; the number of cats receiving SC fluids for Groups I, II, and III were 2, 2, and 1, respectively. Two cats, both from Group I, developed systemic hypertension after entry into the study which was controlled with PO amlodipine. The highest recorded

| Clinical Variable | Overall | Group I | Group II | Group III |
|------------------|---------|---------|----------|-----------|
| Serum creatinine concentration (mg/dL) | 2.40 ± 0.44 | 2.41 ± 0.45 | 2.26 ± 0.45 | 2.56 ± 0.40 |
| Indirect systolic blood pressure (mmHg) | 131 ± 16.8 | 139 ± 16.6 | 122 ± 13.6 | 130 ± 17.1 |
| Urine protein: urine creatinine ratio | 0.53 ± 1.09 | 0.23 ± 0.23 | 0.72 ± 1.28 | 0.61 ± 1.41 |
| Hematocrit (%) | 34.8 ± 5.39 | 33.6 ± 5.70 | 36.7 ± 5.12 | 34.0 ± 6.12 |
| Body weight (kg) | 4.76 ± 1.57 | 5.41 ± 1.31 | 4.91 ± 1.88 | 3.73 ± 0.99 |
| Age (months) | 151 ± 52.2 | 125 ± 63.2 | 152 ± 40.8 | 179 ± 37.5 |

Table 1. Indirect indicators of renal function at study inclusion in cats with IRIS Stage 2 or early Stage 3 CKD treated with Chinese rhubarb (Group I; n = 9), benazepril (Group II; n = 9), or both (Group III; n = 8).

| Variable | Treatment | Time | Treatment × Time |
|----------|-----------|------|------------------|
| Serum creatinine | .35 | .34 | .43 |
| Indirect blood pressure | .90 | .22 | .37 |
| Urine protein: urine creatinine | .92 | .55 | .40 |
| Hematocrit | .65 | .24 | .38 |
| Change in body weight | .71 | .23 | .37 |

Table 2. Serum creatinine concentration, indirect systolic blood pressure, UPC, hematocrit, and change in body weight over time in cats with Stage 2 or early Stage 3 CKD treated with Chinese rhubarb (Group I; n = 9), benazepril (Group II; n = 9), or both (Group III; n = 8).
systolic blood pressures were 170 and 175 mmHg, respectively. The time to development of systemic hypertension after entry into the study was approximately 1 and 3 years, respectively. Neither cat had signs of hypertensive encephalopathy on physical examination or hypertensive retinal changes on fundic examination. Two cats, 1 each from Groups II and III, received PO famotidine for gastrointestinal upset.

Two cats, one each from Groups II and III, received PO methimazole for previously diagnosed hyperthyroidism. Six cats received PO antibiotics for bacterial lower urinary tract infection; the number a of cats from Groups I, II, and III were 1, 2, and 3, respectively. One cat, from Group III, received PO antibiotics for bacterial rhinitis.

Possible adverse effects of rhubarb supplement administration as reported by the pet owner included 2 cats: 1 with lethargy and 1 with vomiting. Both possible adverse effects resolved without specific treatment and rhubarb supplementation was continued. A severe cutaneous drug reaction was the single possible reported adverse effect associated with benazepril administration. This reaction was manifested as widespread erythema, pruritus, and alopecia, which was most severe on the ventrum. Skin scrapings and cytology evaluation were unremarkable. No additional diagnostic investigation such as skin biopsy was performed. The cutaneous reaction completely resolved in the 2 weeks after discontinuation of benazepril. One pet owner reported difficulty administering the rhubarb supplement tablet. All but 2 cats ate the initial renal-specific diet. Both accepted an alternate commercially available renal-specific diet.

Discussion

This study is the first to investigate the effects of a Chinese rhubarb supplement on the progression of naturally occurring CKD in cats. The results failed to detect a significant difference among treatment with rhubarb supplement, benazepril, or both with regard to the progression of CKD as quantified by changes in serum creatinine concentration, body weight, hematocrit, systolic blood pressure, and UPC. The IRIS staging system classifies cats with serum creatinine concentration of 2.5–5.0 mg/dL as Stage 3.19 Cats with IRIS Stage 2 or early Stage 3 CKD (serum creatinine concentration of 1.6–3.5 mg/dL) were chosen for this study. Although this inclusion criterion was arbitrary, cats with later IRIS Stage 3 CKD and beyond, with a potentially greater degree of renal fibrosis already present, were considered less likely to benefit from antifibrotic treatment.

Not finding a significant difference among treatments is only notable with an appropriately powered study. Prestudy power estimates showed that including 6 cats in each group would provide a power of 0.80 for the detection of a 0.4 mg/dL difference in serum creatinine concentrations, a 0.14 difference in UPC, or a 10 mmHg difference in systolic blood pressure. This estimate assumed an intracat correlation over time of...
0.75. This study consisted of at least 8 cats per treatment group. As such, there is expected to be at least an 80% chance that if a significant difference existed it would have been detected.

The diagnosis of feline CKD is essentially one of exclusion. Azotemia because of ureteral obstruction, renal neoplasia, pyelonephritis, and prerenal or postrenal causes must be ruled out. A diagnosis of CKD usually includes small irregular kidneys on abdominal palpation and small, irregular kidneys with a loss of corticomedullary definition of abdominal ultrasound examination and usually does not include renal biopsy. As such, it is possible for an underlying renal disease to go undetected. One cat in this study was found to have bilateral renal TCC on postmortem examination. This neoplasm may have been the cause of renal dysfunction in this cat from the beginning. It is also possible that this cat developed renal TCC subsequent or in addition to CKD. The fact that this cat lived for almost 11 months with relatively stable kidney function, that kidney imaging at inclusion was consistent with CKD and not renal neoplasia, and postmortem examination showed both glomerulosclerosis and interstitial nephritis in addition to renal TCC, makes CKD and subsequent renal TCC most likely. For this reason, this cat was included in the final statistical analysis. To the authors' knowledge, renal TCC or other renal neoplasia has never been associated with rhubarb administration in other species including humans or rodents. Although considered unlikely, rhubarb supplementation as a cause of renal cancer in this cat cannot be completely ruled out.

As expected, cats with IRIS Stage 2 and early Stage 3 CKD live a relatively long time. For this reason, dependent variables other than survival were used to assess response to treatment. Euthanasia is the most common cause of death in cats with CKD and is because of perceived poor quality of life. All deaths in this study were because of euthanasia. Of the 3 cats that were euthanized for nonkidney-related causes, 1 was euthanized because of persistent periruia. It could be argued that this was at least in part related to CKD secondary to polyuria. Other comorbidities whether related to CKD or not that might predispose a cat to periruia include idiopathic cystitis, urinary tract infection, urolithiasis, urinary tract neoplasia, osteoarthritis, and cognitive dysfunction. This cat had multiple negative bacterial urine cultures and unremarkable urinary bladder ultrasound examination making bacterial cystitis, neoplasia, or urolithiasis unlikely. Osteoarthritis was believed to be present in this cat based on crepusitus during joint manipulation. The cat failed to improve with provision of an additional litter box that did not have a climb-up step and medical treatment for osteoarthritis. It was possible that osteoarthritis or reluctance to step up into the litter box initiated the periruia which then became behavioral. Because factors beyond CKD likely played a substantial role in the periruia and subsequent euthanasia in this cat, it was classified as a nonkidney-related death.

A limitation of this study is the duration of time cats were enrolled in the study. The mean duration of enrollment for all cats in this study was approximately 22 months. For case recruitment, referring veterinarians and pet owners received a monetary incentive. The monetary incentive given to the pet owner after 1 year of study participation likely improved compliance and increased the duration of participation. Because of the monetary incentives provided, compliance as it relates to the treatment groups was not further investigated.

A second limitation of this study is that neither pet owners nor investigators were blinded to the treatments and some treatment bias may have occurred. The objective indirect measures of kidney function or consequences thereof, such as serum creatinine concentration, hematocrit, change in body weight, systolic blood pressure, and UPC likely were not affected. Alternatively, the pet owner's perceived quality of life and the decision to euthanize may have been affected.

A third limitation of this study is that GFR was not measured. Serum creatinine concentration indirectly correlates with GFR when certain factors such as lean body mass are held stable. Overall, the cats in this study lost body weight over time. There was no significant difference in body weight among groups at inclusion into the study or in the change in body weight over time. The latter suggests that across groups the effect of the change in body weight as it pertains to serum creatinine concentrations would be similar.

A final limitation of this study is that the benazepril dose was not adjusted based on patient response. Four cats receiving benazepril, 2 each from Groups II and III had UPC persistently ≥0.4. If allowed by study protocol, the benazepril dose may have been increased in these cats. It is possible that allowing for dose escalation of benazepril in this study would have led to improved clinical efficacy in these cats. ACEi may slow the progression of feline CKD, but the evidence is limited. There is more evidence for this effect in other species. Not finding a significant difference among treatment groups suggests that in this population of cats both benazepril and rhubarb affected the progression of CKD similarly or possibly not at all. Without a negative control, it is not possible to make any statement with regard to how the treatments compared to no treatment at all.

The UPC provides prognostic information in feline CKD. As such, it would have been reasonable to either stratify or include a certain degree of proteinuria as an exclusion criterion. The inclusion of proteinuric cats was deemed important as studies using rodent models of kidney disease have shown a decrease in proteinuria with the administration of rhubarb extract. In addition, there is evidence that the effects of ACEi and rhubarb on proteinuria and renal fibrosis are synergistic. Although consistent renal proteinuria (UPC >0.4) was uncommon in this study, the authors felt it was unethical to withhold appropriate treatment of proteinuria. For these reasons, benazepril was chosen as the positive control and a third group of cats treated with both drugs was included in
the study. Treatment of systemic hypertension with amlodipine decreases proteinuria,\(^{31}\) which may have affected the UPC in the 2 cats from Group I that received amlodipine.

Although the UPC at baseline was not significantly different among treatment groups, this does not necessarily mean that they were not clinically different. In a prospective, longitudinal study of geriatric nonazotemic cats, cats that became azotemic started with a UPC of 0.17 as compared to cats that did not become azotemic with UPC of 0.14.\(^{33}\) Considering the relatively small difference between groups in the aforementioned study, the difference between Group I (mean UPC 0.23) and Groups II and III (mean UPC 0.72 and 0.61, respectively) in this study may be clinically relevant. It is not possible to discern how the differences in proteinuria among treatment groups affected these study results.

Hematocrit was chosen as an indirect indicator of renal endocrine function. Endocrine dysfunction in the case of a relative lack of erythropoietin can provide important therapeutic and prognostic information.\(^{23,32}\) The failure to detect and appropriately treat renal anemia leads to lethargy and other signs of systemic illness readily recognized by the pet owner. Anemia associated with CKD is multifactorial; contributing factors include anemia of chronic disease, shortened red blood cell life span, relative erythropoietin deficiency, and gastrointestinal blood loss.\(^{34}\) In this study, early signs of anemia especially when accompanied by gastric upset were treated with famotidine. Although this treatment was directed toward gastric erosion or ulceration that may develop secondary to hypergastrinemia, no further investigation such as gastrointestinal endoscopy was used to corroborate or refute this assumption. In addition, bone marrow sampling to further investigate nonregenerative anemia was not performed in any cat. Finally, hydration status is patient dependent and may have affected the hematocrit. An alternative to assessing renal endocrine function would have been directly quantifying erythropoietin, which would have been interpreted in light of the cat's hematocrit. At the time of the study, a commercial feline erythropoietin assay was not available.

Systemic hypertension frequently is associated with feline CKD.\(^{35}\) As such, systolic blood pressure was monitored throughout the study. There is no evidence that systemic hypertension is more prevalent as CKD progresses. There is evidence in people with CKD that systemic hypertension contributes to deterioration of renal function.\(^{36}\) Although the role of systemic hypertension in the progression of CKD in cats is not well established, there is some histopathologic evidence that it may negatively affect prognosis.\(^{37}\) Control of systemic hypertension in cats with CKD may improve survival in part by decreasing proteinuria.\(^{31}\) We felt it was unethical to withhold amlodipine treatment to cats with hypertensive CKD. To decrease confounding bias and variability and increase power in this study, we tried to select a homogenous population of cats with CKD. Cats had variable clinical monitoring before the study, and it is possible that cats with systemic hypertension at the first visit may have had long-term systemic hypertension. For these reasons, cats with systemic hypertension were excluded from the study. During the study, only 2 cats developed systemic hypertension, and they did so approximately 1 and 3 years after entry, respectively. Both cats were considered at moderate risk for target organ damage based on the degree of systemic hypertension and neither had evidence of complications.\(^{19}\) Because of the frequent monitoring of cats in this study, the amount of time the cats could have been hypertensive was short. For these reasons, the 2 cats that developed systemic hypertension were not removed from the study.

One cat in Group II was reallocated to Group I. The fact that this group change contradicted the goals of random allocation and intention-to-treat was recognized, although the effect to the overall randomness of the study was considered very small. A total of 17 cats in this study received rhubarb for a mean duration of approximately 20 months. As stated previously, it is considered unlikely that rhubarb supplementation was the cause of renal TCC in 1 cat in this study, although it cannot be completely ruled out. Only 2 additional cats showed mild findings that were possible adverse effects of rhubarb administration, suggesting that the rhubarb supplement used in this study is likely safe to administer over a relatively long period of time to cats with Stage 2 or early Stage 3 CKD.

**Conclusion**

Based on the analysis of easily measured clinical indirect indicators of renal excretory and endocrine function, this study failed to find a significant difference in the progression of feline CKD among cats treated with benazepril, rhubarb supplementation, or both at commonly recommended dosages. Further investigation of the effects of rhubarb supplementation as it relates to specific subsets of cats with CKD is warranted.

**Footnotes**

\(^{a}\) Rubenal, Vetoquinol USA, Fort Worth, TX  
\(^{b}\) Benazepril, Teva Pharmaceuticals USA, North Wales, PA  
\(^{c}\) Rubenal Technical Brochure, Vetoquinol USA  
\(^{d}\) E.R.D. Health Screen Urine Tests, Heska, Loveland, CO  
\(^{e}\) Ultrasonic Doppler Flow Detector, Parks Medical Electronics Inc, Aloha, OR  
\(^{f}\) Bili Labs, Bayer Healthcare LLC, Morristown, NJ  
\(^{g}\) Hitachi 911, Roche Diagnostics, Indianapolis, IN  
\(^{h}\) k/d, Hill's Pet Nutrition, Topeka, KS  
\(^{i}\) NF Kidney Function, Purina Veterinary Nutrition, St. Louis, MO  
\(^{j}\) Renal LP, Royal Canin USA, St. Charles, MO  
\(^{k}\) STATA 11, STATA Corp LP, College Station, TX  
\(^{l}\) SAS on Demand, SAS, Cary, NC
Renal K, Vetoquinol USA
Tamil K, JMI-Daniels Pharmaceuticals, St. Petersburg, FL
Amlodipine besylate, Ascend Laboratories LLC, Montvale, NJ
Famotidine, Teva Pharmaceuticals USA, Sellersville, PA
Methimazole, Par Pharmaceutical Companies Inc, Spring Valley, NY

Acknowledgment
The authors acknowledge Sherry Sharp, RVT for her technical assistance. This study was supported by a grant from Vetoquinol.

Conflict of Interest: Authors disclose no conflict of interest.

References
1. Egenvall A, Nedveldt A, Häggström J, et al. Mortality of life-insured Swedish cats during 1999–2006: Age, breed, sex, and diagnosis. J Vet Intern Med 2009;23:1175–1183.
2. Lulich JP. Feline renal failure: Questions, answers, questions. Compend Cont Ed Pract Vet 1992;14:127–151.
3. Boor P, Ostendorf T, Floege J. Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010;6:643–656.
4. Razzaque MS, Taguchi T. Cellular and molecular events leading to renal tubulointerstitial fibrosis. Med Electron Microscope 2002;35:68–80.
5. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508.
6. Chakrabarti S, Syme HM, Brown CA, et al. Histomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction. Vet Pathol 2013;50:147–155.
7. Heyman SN, Khamaisi M, Rosen S, et al. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008;29:998–1006.
8. Fine LG, Orphanides C, Norman JT. Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int Suppl 1998;65:S74–578.
9. Fine LG, Bandyopadhyay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000;75:S22–S26.
10. Makino H, Sugiyama H, Kashiwara N. Apoptosis and extracellular matrix-cell interactions in kidney disease. Kidney Int Suppl 2000;77:S67–S75.
11. Marastoni S, Ligresti G, Lorenzon E, et al. Extracellular matrix: A matter of life and death. Connect Tissue Res 2008;49:203–206.
12. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012;18:1082–1040.
13. Arata S, Ohmi A, Mizukoshi F, et al. Urinary transforming growth factor-beta1 in feline chronic renal failure. J Vet Med Sci 2005;67:1253–1255.
14. Ivanus M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004;13:279–284.
15. Jia ZH, Liu ZH, Zheng JM, et al. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Exp Clin Endocrinol Diabetes 2007;115:571–576.
16. Zhang G, el Nahas AM. The effect of rhubarb extract on experimental renal fibrosis. Nephrol Dial Transplant 1996;11:86–190.
17. Zhang JH, Li LS, Zhang M. Clinical effects of rheum and captopril on preventing progression of chronic renal failure. Chin Med J (Engl) 1990;103:788–793.
18. Miyagawa Y, Takemura N, Hirose H. Assessments of factors that affect glomerular filtration rate and indirect markers of renal function in dogs and cats. J Vet Med Sci 2010;72:1129–1136.
19. International Renal Interest Society. IRIS 2009 staging of CKD. Available at: http://www.iris-kidney.com. Accessed August 8, 2013.
20. Boyd LM, Langston C, Thompson K, et al. Survival in cats with naturally occurring chronic kidney disease (2000–2002). J Vet Intern Med 2008;22:1111–1117.
21. Elliott JB, Barber PJ. Feline chronic renal failure: Clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998;39:78–85.
22. Elliott J, Rawlings JM, Markwell PJ, et al. Survival of cats with naturally occurring chronic renal failure: Effect of dietary management. J Small Anim Pract 2000;41:235–242.
23. King JD, Tasker S, Gunn-Moore DA, et al. Prognostic factors in cats with chronic kidney disease. J Vet Intern Med 2007;21:906–916.
24. Mizutani H, Koyama H, Watanabe T, et al. Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats. J Vet Intern Med 2006;20:1074–1079.
25. Watanabe T, Mishina M. Effects of benazepril hydrochloride in cats with experimentally induced or spontaneously occurring chronic renal failure. J Vet Med Sci 2007;69:1015–1023.
26. Fern RJ, Yesko CM, Thornhill BA, et al. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999;103:39–46.
27. Kagami S, Kuhara T, Okada K, et al. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997;51:664–671.
28. Macconi D. Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol Histopathol 2010;25:655–668.
29. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803–1817.
30. Gross O, Schulze-Lohoff E, Koeppe ML, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004;19:1716–1723.
31. Jepson RE, Elliott J, Brodbelt D, et al. Effect of control of systolic blood pressure on survival in cats with systemic hypertension. J Vet Intern Med 2007;21:402–409.
32. Kuwahara Y, Ohba Y, Kitoh K, et al. Association of laboratory data and death within one month in cats with chronic renal failure. J Small Anim Pract 2006;47:446–450.
33. Jepson R, Brodbelt D, Vallance C, et al. Evaluation of predictors of the development of azotemia in cats. J Vet Intern Med 2009;23:806–813.
34. Pechereau D, Martel P, Braun JP. Plasma erythropoietin concentrations in dogs and cats: Reference values and changes with anaemia and/or chronic renal failure. Res Vet Sci 1997;62:185–188.
35. Kobayashi DL, Peterson ME, Graves TK, et al. Hypertension in cats with chronic renal failure or hyperthyroidism. J Vet Intern Med 1990;4:58–59.
36. Pinitpoulou AG, Pikilidou MI, Lasaridis AN. The effect of antihypertensive drugs on chronic kidney disease: A comprehensive review. Hypertens Res 2013;36:91–101.
37. Mathur S, Brown CA, Dietrich UM, et al. Evaluation of a technique of inducing hypertensive renal insufficiency in cats. Am J Vet Res 2004;65:1006–1013.